CTIS2023-509606-30-00进行中（未招募）1 期
A randomised, double-blind, double-dummy, multicentre, phase III, non inferiority trial of an oral mesalazine formulation in patients with active mild to moderate ulcerative colitis for the induction of remission. - CGRA-0121/ES
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 502
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Be = 18 years of age at Visit 1., For males with female partners of childbearing potential: acceptance to use birth control methods (condom with or without spermicide, or effective methods of birth control of female partner) throughout the trial duration and until 2.5 months after last intake of IMP. Vasectomy or sexual abstinence (if defined as refraining from heterosexual intercourse during the entire period of risk associated with the trial treatment) are also acceptable methods. The investigator is responsible for determining whether the patient has adequate birth control for trial participation., Provide written informed consent., Be willing and able to follow all instructions, undergo all assessments, complete the electronic diary and attend all trial visits., Have UC symptoms for at least 3 months prior to Visit 1, and UC diagnosis established by clinical, histological and endoscopic evidence, extending 15 cm or more from the anal verge., Have active, mild to moderate UC at the time of screening, defined as: - Modified Mayo score 4 - 7, - Mayo endoscopic subscore = 2, confirmed by central reader before randomisation., Have a recent (= 31 days prior to Visit 1) endoscopy documenting the degree and extent of mucosal inflammation; otherwise, an endoscopy must be performed during the screening period to confirm a MES = 2., Be treatment naïve or currently treated with oral mesalazine = 2.5 g per day or rectal mesalazine = 1 g per day (combination of rectal and oral not allowed). Note: patients treated in past flares with higher doses of mesalazine or treated with glucocorticoids will be allowed., Be able and willing to avoid all disallowed medications for the appropriate washout period before randomisation and during the rest trial (see Section 7.6 [of D1_Protocol 2023-509606-30-00] for concomitant medications): Medication group, Route, Washout period; Antibiotics, Systemic, 1 week; Anti-diarrhoeal, Systemic, 1 week; Glucocorticoid, Systemic, 4 weeks; Glucocorticoid, Rectal, 4 weeks, For females of childbearing potential only: willing to perform pregnancy tests, must agree to use effective methods of birth control throughout the trial until the trial ends (T3). Effective methods of birth control include: combined hormonal contraception associated with inhibition of ovulation (oral, intravaginal or transdermal), progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable or implantable), intrauterine device (IUD), intrauterine hormone-releasing system (IUS), bilateral tubal occlusion, vasectomized partner (provided that partner is the sole sexual partner of the clinical trial patient and has documentation of azoospermia) or sexual abstinence (if defined as refraining from heterosexual intercourse during the entire period of risk associated with the trial treatment). The investigator is responsible for determining whether the patient has adequate birth control for trial participation.
排除标准
- •Have known contraindications or sensitivities to the use of the IMPs or any of its components., Suspected or documented infectious enterocolitis within the 1 month prior to the Visit 1., Have previous or current treatment with thiopurines, calcineurin inhibitors, methotrexate, JAK inhibitors and/or biologics., Patients who previously were refractory to treatment with oral or rectal mesalazine., Have a history of or current diagnosis of severe or uncontrolled pulmonary disease, myocarditis or pericarditis., Severe or uncontrolled asthma, that in the opinion of the investigator, would compromise the patient safety (e.g. asthma that has frequent exacerbations or is not controlled with high doses of inhaled glucocorticoids)., Have a history of or current diagnosis of haemorrhagic diathesis., Have an active malignancy or treatment with antineoplastic agents during the last 5 years. Patients with a history of cancer other than colorectal cancer and at least 5 years of uneventful follow-up and no signs of recurrence may be eligible according to the investigator’s decision., Have participated in another clinical trial in which an investigational drug (including investigational vaccines) or invasive investigational medical device has been taken within the past 90 days (or five half-lives of IMP whichever is longer) prior to Visit 1, or simultaneous participation in another clinical trial., Have any condition that, in the opinion of the investigator, may jeopardise the clinical trial conduct according to the protocol (for example, evidence of diseases, medications or laboratory abnormalities that could alter the conduct of the trial)., Be an employee of the investigator or clinical trial unit, with direct involvement in the proposed trial or other studies under the direction of that investigator or clinical trial unit, as well as family members of the employees or the principal investigator., XXXXXXXXXXXXXXXXXXX, Patients unable to understand the informed consent or having a high probability of non-compliance with the trial procedures., Be a person committed to an institution by virtue of an order issued either by judicial or other authorities., Be pregnant, planning a pregnancy or breastfeeding., Have severe UC, as defined by Truelove & Witts ([reference in D1_Protocol 2023-509606-30-00] 32) with the presence of = 6 bloody stools per day, with one or more of the following: a. Temperature > 37.8 ºC. b. Heart rate > 90 beats/minute. c. Haemoglobin concentration < 10 g/dL., Have a history of colonic resection (excluding appendectomy)., Present moderate to severe renal disorder, defined by eGFR < 45 mL/min/1.73m2., Present moderate to severe hepatic disorder, characterised by serum transaminase (ALT or AST) or alkaline phosphatase values (ALP) = 3 x ULN or total bilirubin (TBILI) = 2 x ULN (except Gilbert syndrome)., Have a gastrointestinal disease that in the opinion of the investigator, would have interfered with the patient's participation in this study. Including but not limited to: Crohn’s disease, other forms of colitis, coeliac disease, malabsorption syndromes, present or past colorectal cancer, gastric or duodenal ulcer., Have ulcerative proctitis (restricted to rectum).
研究者
相似试验
已完成
4 期
Comparison of two formulations of ipratropium/salbutamol MDI in the treatment of chronic obstructive pulmonary diseaseCTRI/2016/03/006776Cipla Ltd290
已完成
4 期
A clinical trial to compare the efficacy and safety of two formulations of inhaled ipratropium bromide in patients chronic obstructive pulmonary disease (COPD).CTRI/2015/05/005793Cipla Ltd395
进行中（未招募）
1 期
A randomized, double-blind, double-dummy, multicenter, parallel group study to compare the tolerability and efficacy of once daily vardenafil versus vardenafil PRN versus placebo in men immediately after nerve-sparing prostatectomy for improving erectile function - REINVENT (Recovery of Erection: Intervention with Vardenafil Early Nightly Therapy)MedDRA version: 8.1Level: LLTClassification code 10061461Term: Erectile dysfunctionErectile DysfunctionEUCTR2004-002172-42-GBBayer Healthcare AG
进行中（未招募）
不适用
A randomized, double-blind, double-dummy, multicenter, parallel group study to compare the tolerability and efficacy of once daily vardenafil versus vardenafil PRN versus placebo in men immediately after nerve-sparing prostatectomy for improving erectile functioErectile DysfunctionEUCTR2004-002172-42-ITBAYER
进行中（未招募）
不适用
A randomized, double-blind, double-dummy, multicenter, parallel group study to compare the tolerability and efficacy of once daily vardenafil versus vardenafil PRN versus placebo in men immediately after nerve-sparing prostatectomy for improving erectile function - REINVENT (Recovery of Erection: Intervention with Vardenafil Early Nightly Therapy)MedDRA version: 8.1Level: LLTClassification code 10061461Term: Erectile dysfunctionErectile DysfunctionEUCTR2004-002172-42-DEBayer Healthcare AG1,000